Skip to content

AVEO Pharmaceuticals, Inc.

CIK 0001325879

← back to feed
Revenue (TTM)
$91.85M
+16.3% YoY Q3 Nov 2022
Net Income (TTM)
−$32.15M
+30.0% YoY Q3 Nov 2022
EPS Diluted (TTM)
−$0.93
+30.0% YoY Q3 Nov 2022
Gross Margin
87.8%
Q3 Nov 2022
Operating Margin
-30.0%
Q3 Nov 2022
Net Margin
-35.0%
Q3 Nov 2022
Free Cash Flow (TTM)
−$56.07M
Q3 Nov 2022
Cash
$77.4M
Q3 Nov 2022
Total Debt
$16.2M
Q3 Nov 2022
Shares Outstanding
34.76M sh
Q3 Nov 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings